6UCF image
Deposition Date 2019-09-16
Release Date 2020-03-18
Last Version Date 2024-10-16
Entry Detail
PDB ID:
6UCF
Title:
N123-VRC34_pI4 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.29 Å
R-Value Free:
0.18
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:HIV fusion peptide
Chain IDs:C (auth: A)
Chain Length:8
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:N123-VRC34_pI4 heavy chain
Chain IDs:B (auth: H)
Chain Length:229
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:N123-VRC34_pI4 light chain
Chain IDs:A (auth: L)
Chain Length:213
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.
Cell Host Microbe 27 531 ? (2020)
PMID: 32130953 DOI: 10.1016/j.chom.2020.01.027

Abstact

Rare mutations have been proposed to restrict the development of broadly neutralizing antibodies against HIV-1, but this has not been explicitly demonstrated. We hypothesized that such rare mutations might be identified by comparing broadly neutralizing and non-broadly neutralizing branches of an antibody-developmental tree. Because sequences of antibodies isolated from the fusion peptide (FP)-targeting VRC34-antibody lineage suggested it might be suitable for such rare mutation analysis, we carried out next-generation sequencing (NGS) on B cell transcripts from donor N123, the source of the VRC34 lineage, and functionally and structurally characterized inferred intermediates along broadly neutralizing and poorly neutralizing developmental branches. The broadly neutralizing VRC34.01 branch required the rare heavy-chain mutation Y33P to bind FP, whereas the early bifurcated VRC34.05 branch did not require this rare mutation and evolved less breadth. Our results demonstrate how a required rare mutation can restrict development and shape the maturation of a broad HIV-1-neutralizing antibody lineage.

Legend

Protein

Chemical

Disease

Primary Citation of related structures